WO2001076591A1 - Treatment of pulmonary disorders by inducing alveoli formation - Google Patents
Treatment of pulmonary disorders by inducing alveoli formation Download PDFInfo
- Publication number
- WO2001076591A1 WO2001076591A1 PCT/US2001/011276 US0111276W WO0176591A1 WO 2001076591 A1 WO2001076591 A1 WO 2001076591A1 US 0111276 W US0111276 W US 0111276W WO 0176591 A1 WO0176591 A1 WO 0176591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rarα
- antagonist
- specific
- rar
- receptor
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract description 29
- 208000019693 Lung disease Diseases 0.000 title abstract description 3
- 230000001939 inductive effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 210000004072 lung Anatomy 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 230000006378 damage Effects 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims description 74
- 108091008726 retinoic acid receptors α Proteins 0.000 claims description 74
- 239000005557 antagonist Substances 0.000 claims description 65
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 59
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 59
- 230000000694 effects Effects 0.000 claims description 33
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims description 29
- 108091008761 retinoic acid receptors β Proteins 0.000 claims description 29
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 claims description 24
- 108091008760 retinoic acid receptors γ Proteins 0.000 claims description 24
- 239000000556 agonist Substances 0.000 claims description 22
- 239000000443 aerosol Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 abstract description 6
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 description 39
- 241000700159 Rattus Species 0.000 description 22
- 102000027483 retinoid hormone receptors Human genes 0.000 description 18
- 108091008679 retinoid hormone receptors Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 14
- 229930002330 retinoic acid Natural products 0.000 description 14
- 108010038912 Retinoid X Receptors Proteins 0.000 description 13
- 102000034527 Retinoid X Receptors Human genes 0.000 description 13
- 150000004492 retinoid derivatives Chemical class 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 210000003456 pulmonary alveoli Anatomy 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 108091027981 Response element Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000012343 cottonseed oil Nutrition 0.000 description 6
- 239000002385 cottonseed oil Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 230000011360 lung alveolus development Effects 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 230000007040 lung development Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000005077 saccule Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WGLMBRZXZDAQHP-UHFFFAOYSA-N BMS 195614 Chemical compound C=1C=C2C(C)(C)CC=C(C=3C=C4C=CC=CC4=NC=3)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 WGLMBRZXZDAQHP-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101000957333 Homo sapiens Muscleblind-like protein 3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100038751 Muscleblind-like protein 3 Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 1
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 description 1
- 102000026043 Retinoid X Receptor alpha Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000030541 receptor transactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000013274 transthoracic needle biopsy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
Definitions
- This invention concerns the use of isotype-specific retinoic acid receptor (RAR) agonists and antagonists for the modulation of alveolar destruction and/or to promote the formation of alveoli in mammalian lung tissue deficient in adequate numbers of functional alveoli.
- RAR retinoic acid receptor
- the lung functions to provide an interface for the exchange of gases between blood and the atmosphere.
- the agents of this exchange are numerous small sacs termed alveoli (in adult humans about 300,000,000 per lung) that provide a gas permeable-liquid impermeable barrier between the gas and liquid phases. Between the alveoli are numerous capillaries carrying deoxygenated blood to the lung from the tissues and oxygenated blood from the alveoli to the tissues.
- the partial pressure of oxygen in the lungs is approximately 100 mm Hg at sea level; at this pressure the binding of oxygen by hemoglobin in the erythrocytes is favored.
- the alveoli thus provide a means for presenting the oxygen to hemoglobin to permit the conversion of deoxyhemoglobin to hemoglobin. Because the exchange occurs at the surface of the gas/blood barrier, alveoli have evolved as a means for providing extremely high surface area in a compact overall area, thus maximizing possible gas exchange. Lack of adequate gas exchange would lead to disability, which could progress to death.
- BPD bronchiopulmonary dysplasia
- emphysema a disease of prematurely born infants, and is characterized mainly by a failure of the infant to form a sufficient number of appropriately-sized alveoli.
- Emphysema a disease of middle and advanced age, appears to be due to progressive proteinase-induced alveolar destruction.
- alveoli formation has been studied from a gross developmental standpoint, and seems to be similar in rat, mouse, and human.
- the process includes the subdivision (septation) of the saccules that constitute the gas-exchange region of the immature lung. Septation results in the formation of smaller, more numerous gas exchange structures (alveoli).
- the timing of the onset and cessation of septation vary among species, but both onset and cessation are critical to the formation of alveoli of the size and number needed for adequate oxygenation.
- ATRA can have a multiplicity of physiological effects.
- the retinoid receptors when bound by an appropriate ligand, are mediators of various life processes, including reproduction, metabolism, differentiation, hematopoiesis, and embryogenesis.
- the therapeutic use of the pan-agonist ATRA may not be desirable in all instances.
- the present invention is directed to methods and compositions for modulating the formation of alveoli in mammalian lung tissue.
- the invention comprises a therapeutic method for inducing the formation of alveoli in mammalian lung tissue by administration of a composition comprising a therapeutically effective amount of a ligand that is an RAR ⁇ antagonist and that does not have RAR ⁇ agonist activity.
- a composition comprising a therapeutically effective amount of a ligand that is an RAR ⁇ antagonist and that does not have RAR ⁇ agonist activity.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not specific to either the RAR ⁇ or the RAR ⁇ receptor.
- the ligand is specific to RAR ⁇ isotypes.
- such a ligand is a retinoid.
- K,* the ligand concentration at which 50% of the target RAR receptors are complexed with the ligand
- RAR receptor at least 10 times, preferably at least 25 times, even more preferably at least 50 times, and most preferably at least 100 times greater than the K, for the binding of the same ligand to an RXR receptor. Determination of the K d at an RAR or RXR receptor for a given ligand is a routine matter.
- agonist is meant a retinoid receptor ligand that will cause the activation of transcription at a gene having an appropriate retinoid receptor response element.
- retinoid receptor ligand that will inhibit the activation of transcription by the retinoid receptor at a gene having an appropriate retinoid receptor response element in the presence of an antagonist of the retinoid receptor.
- inverse agonist is meant a retinoid receptor ligand that will inhibit the expression of transcription at a gene having an appropriate retinoid receptor response element beyond a basal expression level existing in the absence of an agonist of the retinoid receptor.
- one uses a compound that is an RAR ⁇ agonist.
- it is an antagonist of at least one of RAR ⁇ or RAR ⁇ .
- one can use a cocktail of compounds that collectively act as an RAR ⁇ antagonist, RAR ⁇ antagonist and an RAR ⁇ agonist.
- the invention is directed to therapeutic compositions for the treatment of an emphysemic mammal, or of a mammal suffering from bronchopulmonary dysplasia, comprising a therapeutically effective amount of an ligand that is an RAR ⁇ antagonist and that does not have RAR antagonist activity at all RAR isotypes.
- the RAR ⁇ antagonist has specific RAR modulating activity at the RAR ⁇ receptor, and is also an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not specific to either the RAR ⁇ or the RAR ⁇ receptor.
- the ligand is specific to RAR ⁇ isotypes. Preferably such a ligand is a retinoid.
- the RAR ⁇ antagonist may be used either as the only active ingredient in the composition, or in combination with one or more additional therapeutically active ingredients.
- the additional therapeutically active ingredient is a retinoid; in a preferred aspect, an additional therapeutically active ingredient is another RAR-active ligand, for example, all-tr ⁇ ras'-retinoic acid.
- RAR-active retinoid is meant that the retinoid has antagonist, agonist, or inverse agonist (negative hormone) activity at an RAR receptor.
- terapéuticaally effective amount is meant that the amount of the RAR-specific therapeutic agent is sufficient, either as the result of a single dose, or as the result of multiple doses over the term of therapy, to decrease the rate of alveolar destruction in an emphysemic mammal, or to promote the growth of alveolar septa in said mammal.
- the present invention is directed to compositions and methods for the treatment or prevention of alveolar destruction and/or to promote the formation of alveoli in mammalian lungs deficient in adequate numbers of functional alveoli.
- Such methods and compositions involve RAR-active retinoids, therapeutic compositions containing such agents, and methods for their use.
- the retinoid receptors are part of the steroid/thyroid/vitamin D superfamily of nuclear receptors.
- the retinoid receptors include the retinoic acid receptors (RAR) and the retinoid X receptor (RXR).
- RAR and RXR receptors are single chain polypeptides containing a number of structural domains in common: a ligand binding domain, a sequence-specific DNA binding domain, and a leucine zipper motif. In the presence of ligand, the single RAR or RXR chains can, by virtue of the leucine zipper, form dimers.
- the RAR chain is believed to exist in vivo exclusively as an RAR/RXR heterodimer.
- RXR may form heterodimers with RAR or other members of the superfamily, such as the vitamin D receptor and the thyroid receptor.
- Retinoid receptor dimers are effective transcription factors regulating gene transcription by binding to retinoic acid response elements (RAREs) or retinoid X response elements (RXREs) present in (or near) the promoters of retinoid responsive genes, or by negatively regulating the enhancer functions of other transcription factors.
- RAREs retinoic acid response elements
- RXREs retinoid X response elements
- RAR isotypes include RAR ⁇ , RAR ⁇ , and RAR ⁇
- described RXR isotypes include RAR ⁇ , RAR ⁇ , and RAR ⁇ .
- each receptor class these isotypes have sequence homology, but are encoded by different genes.
- Within each isotype several isoforms have been described; these isoforms differ in their N terminals and are generated by alternative splicing and/or differential usage of more than one promoter. See e.g., Nagpal & Chandraratna, Current Pharm. Design 2:295-316 (1996) and Mangelsdorf et al., The Retinoid Receptors in The Retinoids: Biology, Chemistry and Medicine Ch. 8(2d ed.
- RAR e.g., ATRA
- RXR e.g., TTNB
- KJ disassociation constant
- K d is defined as the concentration of ligand at which 50% of the receptors are ligand bound. Even more preferably, K, is at least 25 times lower for the target receptor than for untargeted receptors. Most preferably, K d is at least 50, or at least 100, times lower for the target receptor than for untargeted receptors.
- compositions for the treatment or prevention of alveolar destruction and/or the promotion of alveolar formation in a mammal comprise a ligand that is an RAR ⁇ antagonist and that does not have RAR antagonist activity for the RAR ⁇ isotype.
- the RAR ⁇ antagonist has specific RAR modulating activity at the RAR ⁇ receptor, and is not an RAR ⁇ agonist and preferably is an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not specific to either the RAR ⁇ or the RAR ⁇ receptor.
- the ligand is specific to RAR ⁇ isotypes. Preferably such a ligand is a retinoid.
- Alveolar destruction may be the result of a pathological condition such as emphysema.
- Treatment to promote alveolar formation may be in response to a condition such as bronchopulmonary dysplasia (BPD).
- BPD bronchopulmonary dysplasia
- Another aspect of the invention provides methods for the treatment of or prevention of alveolar destruction and/or the promotion of alveolar formation in a mammal, comprising administering a therapeutic amount of a composition comprising a retinoid receptor ligand that is an RAR ⁇ antagonist.
- the RAR ⁇ antagonist has specific RAR modulating activity at the RAR ⁇ receptor, and is an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not an antagonist of the RAR ⁇ receptor.
- the RAR ⁇ receptor antagonist has specific RAR modulating activity at the RAR ⁇ receptor and is not specific to either the RAR ⁇ or the RAR ⁇ receptor.
- the ligand is specific to RAR ⁇ isotypes. Preferably such a ligand is a retinoid.
- compositions of the present invention can be administered in any therapeutically effective manner or form, and in conjunction with any pharmacologically effective vehicle.
- the compositions of the invention may be administered in the form of an inhalant as a powdered or liquid aerosol.
- Such a formulation may comprise the active agent solubilized in a micronized hydrophobic/hydrophilic emulsion.
- Such compositions are well known to those of skill in the art.
- compositions may be administered systemically, such as intravenously by infusion, or by intraperitoneal injection.
- intravenous administration the necessary composition of pharmacologically effective infusion solutions, such as the proper electrolyte balance and tonicity are well known to those of skill in the art, and therefore formulation of the compositions of the present invention with such solutions would be well within the ability of such a person with the disclosure of this application.
- administration of drugs by intraperitoneal injection is well known, and pharmacological vehicles are well known.
- RAR ⁇ antagonists have the following formula, where X is CR 2 , 0, S, or Nr; R' and R" can be either H or a lower alkyl; Ar and Ar' are each a single ring aryl moiety; and B is either CR'CH, CHCR', COO, and OOC, COHN, NHOC, CSHN, or NHSC.
- Variation of this transactivation assay permits testing ligands as RAR antagonists, or antagonists of a given target isotype.
- a competitive assay involving the use of a stimulatory concentration of a known agonist of a given receptor (for example, ATRA is known to be an agonist of all RAR isotypes), and measuring the reduction in a reporter gene expression (e.g., CAT expression) as a function of the added candidate compound.
- membrane preparations containing cloned retinoid receptors can be used, and the receptors loaded with a known radiolabeled ligand. The release of radioactivity from these preparations as a function of test compound concentration can be determined. The lower the Kj for a given ligand, the more likely the ligand will be effective as a modulator of receptor activity. Further disclosure is available in, e.g., U.S. Patent No. 5,776,699, previously incorporated by reference herein.
- Example 1 Involvement of RAR Receptors in Alveolus Formation
- alveolus formation can continue up to the age of 20.
- the rate of increase in specific lung volume (expressed as cm 3 / 100 g body weight) in rats is greatest within the first 10 days following birth, after which it increases at a less steep rate.
- the lung's efficiency is determined not merely by the volume of air that can be contained in the lung, but by the alveolar surface area, which is a function of tissue growth within the lung.
- Burri et al., Anat. Rec. 178:711-730 (1973) and Burri, Anat. Rec. 180: 77-98 (1974) performed extensive studies of the postnatal rat lung and demonstrated that three developmental phases can be shown. In the first stage (day 1-4) there is a massive expansion of the lung's volume. In the second stage, there is an increase in lung tissue proliferation due to septation, including alveolar and capillary surface areas. In the final stage (day 21 to adult) there is a period of concomitant tissue redistribution, lengthening of the septa and alveolar growth.
- rat pups were subjected to identical daily injections until day 13.
- a set of rat pups were sacrificed at day 4 and at day 21 by anesthesia with phenobarbitol sodium and scission of the abdominal aorta.
- rat lungs were fixed and histological sections prepared essentially as described in Massaro et al., Am. J. Physiol. 270: L305 (1996), incorporated by reference herein. The histological sections were viewed and photographs taken under light microscopy.
- the data also indicate that the increase in lung air volume seen in the first few days is an event independent from the presence or absence of RAR receptors or the presence or absence of an RAR modulating ligand.
- the septation stage of lung development can therefore be uncoupled from the increase in lung volume seen immediately post birth.
- modulating of RAR receptors can be used to specifically affect septation without modulating other events in alveolar formation.
- RAR receptors appear to be an endogenous modulator of alveolus formation.
- agents having specific RAR modulating activity e.g., RAR ⁇ antagonist activity
- RAR ⁇ antagonist activity permits more specific targeting of alveolar formation.
- treatment with a RAR ⁇ antagonist plus all-trans retinoic acid may well augment the effect of either agent alone, allowing the use of lower doses of these drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of a alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.
Description
"TREATMENT OF PULMONARY DISORDERS BY INDUCING ALVEOLI FORMATION"
This work was supported by National Heart, Lung, and Blood Institute grants HL- 37666 and HL-20366 and the government of the United States has certain rights thereto.
FIELD OF THE INVENTION
This invention concerns the use of isotype-specific retinoic acid receptor (RAR) agonists and antagonists for the modulation of alveolar destruction and/or to promote the formation of alveoli in mammalian lung tissue deficient in adequate numbers of functional alveoli.
BACKGROUND OF THE INVENTION
Among aerobic animals, the lung functions to provide an interface for the exchange of gases between blood and the atmosphere. The agents of this exchange are numerous small sacs termed alveoli (in adult humans about 300,000,000 per lung) that provide a gas permeable-liquid impermeable barrier between the gas and liquid phases. Between the alveoli are numerous capillaries carrying deoxygenated blood to the lung from the tissues and oxygenated blood from the alveoli to the tissues. The partial pressure of oxygen in the lungs is approximately 100 mm Hg at sea level; at this pressure the binding of oxygen by hemoglobin in the erythrocytes is favored. The alveoli thus provide a means for presenting the oxygen to hemoglobin to permit the conversion of deoxyhemoglobin to hemoglobin. Because the exchange occurs at the surface of the gas/blood barrier, alveoli have evolved as a means for providing extremely high surface area in a compact overall area, thus maximizing possible gas exchange. Lack of adequate gas exchange would lead to disability, which could progress to death.
Diseases that result in fewer alveoli can be quite serious, and are common causes of inadequate oxygenation and resultant disability and/or death. Among such diseases are bronchiopulmonary dysplasia (BPD) and emphysema. BPD is a disease of prematurely born infants, and is characterized mainly by a failure of the infant to form a sufficient number of
appropriately-sized alveoli. Emphysema, a disease of middle and advanced age, appears to be due to progressive proteinase-induced alveolar destruction.
The process of alveoli formation has been studied from a gross developmental standpoint, and seems to be similar in rat, mouse, and human. The process includes the subdivision (septation) of the saccules that constitute the gas-exchange region of the immature lung. Septation results in the formation of smaller, more numerous gas exchange structures (alveoli). The timing of the onset and cessation of septation vary among species, but both onset and cessation are critical to the formation of alveoli of the size and number needed for adequate oxygenation.
The molecular basis of the initiation and cessation of alveoli formation have not been as well understood as the structural events and timing accompanying alveolar development. Knowledge of the molecular signals that initiate and end septation, and that govern the spacing of septa relative to the O2-demand, are virtually unknown; however, several lines of evidence suggest that certain retinoids (retinoic acid and its derivatives) may play a key signaling role. In Massaro et al., Nature Medicine 30 3:675 (1997), hereby incorporated by reference herein, rats were treated with elastase, causing destruction of alveolar walls in a manner similar to that seen in emphysema. Treatment of the rats with all-trans-retinoic acid (ATRA), an antagonist of all RAR isotypes, appeared to reverse this destruction. Similarly, treatment of newborn rats (which are bom with immature lungs lacking an adult complement of alveoli) with ATRA induced the formation of an increased number of alveoli in rats without enlarging the lung. See Massaro et al., Am. J. Physiol. 270: L305 (1996) incorporated by reference herein.
However, ATRA can have a multiplicity of physiological effects. The retinoid receptors, when bound by an appropriate ligand, are mediators of various life processes, including reproduction, metabolism, differentiation, hematopoiesis, and embryogenesis. Thus, the therapeutic use of the pan-agonist ATRA may not be desirable in all instances.
Additional means for inhibiting alveolar destruction and/or promoting the formation of alveoli in a postnatal aerobic animal, particularly a mammal such as a human are desirable. Additionally, it would be useful to have more specific therapeutic methods treat such a condition.
SUMMARY OF THE INVENTION
The present invention is directed to methods and compositions for modulating the formation of alveoli in mammalian lung tissue. In one embodiment the invention comprises a therapeutic method for inducing the formation of alveoli in mammalian lung tissue by administration of a composition comprising a therapeutically effective amount of a ligand that is an RARα antagonist and that does not have RARβ agonist activity. Preferably it is also an RARβ antagonist. In a preferred aspect, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not an antagonist of the RARγ receptor. In an alternative aspect of this embodiment, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not specific to either the RARβ or the RARγ receptor. Even more preferably, the ligand is specific to RARα isotypes. Preferably such a ligand is a retinoid.
By "specific RAR modulating activity" is meant that such a compound has a disassociation constant (K,*) (the ligand concentration at which 50% of the target RAR receptors are complexed with the ligand) at an RAR receptor at least 10 times, preferably at least 25 times, even more preferably at least 50 times, and most preferably at least 100 times greater than the K,, for the binding of the same ligand to an RXR receptor. Determination of the Kd at an RAR or RXR receptor for a given ligand is a routine matter. Membrane preparations of host cells expressing a cloned RAR or RXR receptor, and the amino acid and nucleotide sequences of such receptors, have been described in various publications available, and within the knowledge of, the person of ordinary skill in the art. For example, U.S. Patent No. 5,776,699, to Klein et al., describes assays employing RAR and RXR, and PCT Publication No. W093/11755 discloses ligand binding assays. These references are now incorporated by reference herein in their entirety.
By "agonist" is meant a retinoid receptor ligand that will cause the activation of transcription at a gene having an appropriate retinoid receptor response element.
By "antagonist" is meant a retinoid receptor ligand that will inhibit the activation of transcription by the retinoid receptor at a gene having an appropriate retinoid receptor response element in the presence of an antagonist of the retinoid receptor.
By "inverse agonist" is meant a retinoid receptor ligand that will inhibit the expression of transcription at a gene having an appropriate retinoid receptor response element beyond a basal expression level existing in the absence of an agonist of the retinoid receptor.
In one embodiment one uses a compound that is an RARγ agonist. Preferably, it is an antagonist of at least one of RARβ or RARα. In one embodiment one can use a cocktail of compounds that collectively act as an RARα antagonist, RARβ antagonist and an RARγ agonist.
In another embodiment, the invention is directed to therapeutic compositions for the treatment of an emphysemic mammal, or of a mammal suffering from bronchopulmonary dysplasia, comprising a therapeutically effective amount of an ligand that is an RARα antagonist and that does not have RAR antagonist activity at all RAR isotypes. In a preferred aspect of this embodiment, the RARα antagonist has specific RAR modulating activity at the RARα receptor, and is also an antagonist of the RARβ receptor. In another preferred aspect, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not an antagonist of the RARγ receptor. In an alternative aspect of this embodiment, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not specific to either the RARβ or the RARγ receptor. In one embodiment, the ligand is specific to RARα isotypes. Preferably such a ligand is a retinoid.
The RARα antagonist may be used either as the only active ingredient in the composition, or in combination with one or more additional therapeutically active ingredients. In one aspect, the additional therapeutically active ingredient is a retinoid; in a preferred aspect, an additional therapeutically active ingredient is another RAR-active ligand, for example, all-trαras'-retinoic acid.
By "RAR-active retinoid" is meant that the retinoid has antagonist, agonist, or inverse agonist (negative hormone) activity at an RAR receptor.
By "therapeutically effective amount" is meant that the amount of the RAR-specific therapeutic agent is sufficient, either as the result of a single dose, or as the result of multiple doses over the term of therapy, to decrease the rate of alveolar destruction in an emphysemic mammal, or to promote the growth of alveolar septa in said mammal.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compositions and methods for the treatment or prevention of alveolar destruction and/or to promote the formation of alveoli in mammalian lungs deficient in adequate numbers of functional alveoli. Such methods and compositions involve RAR-active retinoids, therapeutic compositions containing such agents, and methods for their use.
The retinoid receptors are part of the steroid/thyroid/vitamin D superfamily of nuclear receptors. The retinoid receptors include the retinoic acid receptors (RAR) and the retinoid X receptor (RXR). The RAR and RXR receptors are single chain polypeptides containing a number of structural domains in common: a ligand binding domain, a sequence-specific DNA binding domain, and a leucine zipper motif. In the presence of ligand, the single RAR or RXR chains can, by virtue of the leucine zipper, form dimers. The RAR chain is believed to exist in vivo exclusively as an RAR/RXR heterodimer. RXR may form heterodimers with RAR or other members of the superfamily, such as the vitamin D receptor and the thyroid receptor.
Retinoid receptor dimers are effective transcription factors regulating gene transcription by binding to retinoic acid response elements (RAREs) or retinoid X response elements (RXREs) present in (or near) the promoters of retinoid responsive genes, or by negatively regulating the enhancer functions of other transcription factors.
Described RAR isotypes include RARβ, RARα, and RARγ, and described RXR isotypes include RARβ, RARα, and RARγ. Within each receptor class, these isotypes have sequence homology, but are encoded by different genes. Within each isotype several isoforms have been described; these isoforms differ in their N terminals and are generated by alternative splicing and/or differential usage of more than one promoter. See e.g., Nagpal & Chandraratna, Current Pharm. Design 2:295-316 (1996) and Mangelsdorf et al., The Retinoid Receptors in The Retinoids: Biology, Chemistry and Medicine Ch. 8(2d ed. Sporn et al. eds. 1994), both of which are hereby incorporated by reference herein.
Depending both upon the ligand and the nature (e.g., RAR or RXR; isotype; isoform) of the monomer chains contained in the dimers, an enormous variety of biological responses regulated by the retinoid receptors are possible.
Ligands specific to RAR (e.g., ATRA) or RXR (e.g., TTNB), and to specific RAR isotypes have been described. See e.g., Nagpal & Chandraratna, Current Pharm. Design 2:295-316 (1996), incorporated by reference herein. Therefore, the design and/or selection of RAR-specific ligands, and of RAR isotype-specific ligands is well within the ability of the person of ordinary skill in the art.
By "specific" to a given retinoid receptor is meant that the disassociation constant (KJ for the binding of the ligand to a given target receptor or receptor isotype or isoform is at least 10 times lower than the Kd value for the ligand and a non-target receptor or receptor isotype or isoform. Kd is defined as the concentration of ligand at which 50% of the receptors are ligand bound. Even more preferably, K,, is at least 25 times lower for the target receptor than for untargeted receptors. Most preferably, Kd is at least 50, or at least 100, times lower for the target receptor than for untargeted receptors.
An aspect of the present invention comprises compositions for the treatment or prevention of alveolar destruction and/or the promotion of alveolar formation in a mammal. Such compositions comprise a ligand that is an RARα antagonist and that does not have RAR antagonist activity for the RARγ isotype. In a preferred aspect of this embodiment, the RARα antagonist has specific RAR modulating activity at the RARα receptor, and is not an RARβ agonist and preferably is an antagonist of the RARβ receptor. In another preferred aspect, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not an antagonist of the RARγ receptor. In an alternative embodiment of this embodiment, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not specific to either the RARβ or the RARγ receptor. In a different embodiment, the ligand is specific to RARα isotypes. Preferably such a ligand is a retinoid.
Alveolar destruction may be the result of a pathological condition such as emphysema. Treatment to promote alveolar formation may be in response to a condition such as bronchopulmonary dysplasia (BPD).
Another aspect of the invention provides methods for the treatment of or prevention of alveolar destruction and/or the promotion of alveolar formation in a mammal, comprising administering a therapeutic amount of a composition comprising a retinoid receptor ligand that is an RARα antagonist. In a preferred aspect of this embodiment, the RARα antagonist has specific RAR modulating activity at the RARα receptor, and is an antagonist of the RARβ receptor. In another preferred aspect, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not an antagonist of the RARγ receptor. In an alternative embodiment of this embodiment, the RARα receptor antagonist has specific RAR modulating activity at the RARα receptor and is not specific to either the RARβ or the RARγ receptor. In one embodiment, the ligand is specific to RARα isotypes. Preferably such a ligand is a retinoid.
The above-mentioned embodiments and aspects are clearly useful for the treatment of medical conditions, such as emphysema and BPD, which have been heretofore difficult or impossible to treat without a lung transplant. As indicated above, use of the RARα antagonist in combination with another agent with activity in treatment of alveolar deficiencies, such as a RARβ antagonist or all-trans-retinoic acid, is useful as well. Such methods and compositions may provide a synergistic therapeutic effect and/or permit the use of lower effective doses of ATRA or another therapeutic agent (the RARβ antagonist) (and the RARα antagonist), thus reducing the prospect of undesired side effects resulting from the use higher concentrations of either agent when used alone.
The compositions of the present invention can be administered in any therapeutically effective manner or form, and in conjunction with any pharmacologically effective vehicle. For example, in a particularly preferred aspect, the compositions of the invention may be administered in the form of an inhalant as a powdered or liquid aerosol. Such a formulation may comprise the active agent solubilized in a micronized hydrophobic/hydrophilic emulsion. Such compositions are well known to those of skill in the art.
Alternatively, the compositions may be administered systemically, such as intravenously by infusion, or by intraperitoneal injection. For intravenous administration, the necessary composition of pharmacologically effective infusion solutions, such as the proper electrolyte balance and tonicity are well known to those of skill in the art, and therefore
formulation of the compositions of the present invention with such solutions would be well within the ability of such a person with the disclosure of this application. Similarly, administration of drugs by intraperitoneal injection is well known, and pharmacological vehicles are well known.
Synthesis of candidate compounds having specific RAR modulating activity is well- known in the art. For example, among other references, the synthesis of RAR ligands is disclosed in U.S. Patents No. 5,739,338; 5,728,846; 5,760,276; 5,877,207; the disclosures of all of which is incorporated by reference herein. The synthesis of RARα-specific antagonists is disclosed in U.S. Patents No. 5,663,357; 5,675,024; and 5,856,490, also incorporated by reference herein. Synthesis of RAR-γ specific agonists is dislosed in Swann et al., European Patent Application No. EP 0747347 and in Reczek et al., Skin Pharmacol. 8: 292-299 (1995), also incorporated herein by reference. One group of specific RARβ antagonists have the following formula, where X is CR2, 0, S, or Nr; R' and R" can be either H or a lower alkyl; Ar and Ar' are each a single ring aryl moiety; and B is either CR'CH, CHCR', COO, and OOC, COHN, NHOC, CSHN, or NHSC.
Additionally, the construction of combinatorial libraries of compounds suitable for screening as RAR-selective ligands is now commonplace and well known to those of skill in the art.
Likewise, methods of screening candidate compounds for Specific RAR modulating activity is routine and well-known in the art. For example, U.S. Patent 5,455,265, incorporated by reference herein, describes a chimeric receptor transactivation assay which tests for RAR-agonist and antagonist activity in the RAR-α, RAR-β, RAR-γ, RXR-α receptor subtypes. Briefly, this assay employs chimeric proteins containing an RAR ligand-binding domain and a heterologous polypeptide segment having the ability to bind to a response element (RE) , in turn facilitating transcription of a specific, measurable target gene, such as cnloramphenicol acetyltransferase (CAT) . Only an agonist of the given RAR isotype whose
ligand binding domain comprises part of the chimeric protein will permit the activation of CAT transcription and expression. These results can be compared with those obtained using chimeric proteins having non-target ligand binding moieties. For example, those ligands able to stimulate CAT synthesis when used in combination with chimeric proteins having RAR binding domains, but not those having RXR ligand binding domains, will be RAR specific agonists.
Variation of this transactivation assay permits testing ligands as RAR antagonists, or antagonists of a given target isotype. A competitive assay involving the use of a stimulatory concentration of a known agonist of a given receptor (for example, ATRA is known to be an agonist of all RAR isotypes), and measuring the reduction in a reporter gene expression (e.g., CAT expression) as a function of the added candidate compound.
Additionally, straightforward receptor binding studies can be performed as competition, rather than transactivation assays. For example, and without limitation, membrane preparations containing cloned retinoid receptors can be used, and the receptors loaded with a known radiolabeled ligand. The release of radioactivity from these preparations as a function of test compound concentration can be determined. The lower the Kj for a given ligand, the more likely the ligand will be effective as a modulator of receptor activity. Further disclosure is available in, e.g., U.S. Patent No. 5,776,699, previously incorporated by reference herein.
Example 1 : Involvement of RAR Receptors in Alveolus Formation
In most mammals new alveoli are formed postnatally; thus the lung of many newborn mammals is immature, and not merely a smaller version of the adult lung. For example, in humans alveolus formation can continue up to the age of 20.
The study of alveolus development in newborn mammals, in this case newborn rats, therefore provides an opportunity to study the effect of various agents on alveolus formation. The rate of increase in specific lung volume (expressed as cm3/ 100 g body weight) in rats is greatest within the first 10 days following birth, after which it increases at a less steep rate.
However, the lung's efficiency is determined not merely by the volume of air that can be contained in the lung, but by the alveolar surface area, which is a function of tissue growth
within the lung. Burri et al., Anat. Rec. 178:711-730 (1973) and Burri, Anat. Rec. 180: 77-98 (1974) performed extensive studies of the postnatal rat lung and demonstrated that three developmental phases can be shown. In the first stage (day 1-4) there is a massive expansion of the lung's volume. In the second stage, there is an increase in lung tissue proliferation due to septation, including alveolar and capillary surface areas. In the final stage (day 21 to adult) there is a period of concomitant tissue redistribution, lengthening of the septa and alveolar growth.
In this example, healthy 3 -day old Sprague-Dawley rat pups were injected intraperitoneally with either cottonseed oil 5 (carrier) or with 5 μl/gram cottonseed oil containing 1.7 mM BMS 195614, a retinoid with RARα antagonist activity. Therefore, with regard to RARα, this drug has an activity opposite to that of ATRA.
Following the initial injection, the rat pups were subjected to identical daily injections until day 13. A set of rat pups were sacrificed at day 4 and at day 21 by anesthesia with phenobarbitol sodium and scission of the abdominal aorta. Following sacrifice, rat lungs were fixed and histological sections prepared essentially as described in Massaro et al., Am. J. Physiol. 270: L305 (1996), incorporated by reference herein. The histological sections were viewed and photographs taken under light microscopy.
Histological sections show that at age 14 days alveoli were smaller, and the degree of septation greater, in rats that had been treated with a RARα antagonist daily from age 3 through 13 days (the separation stage of lung development), than in rats treated with cottonseed oil alone.
The differences in alveolar dimensions between treated and untreated rat pups were so pronounced, they were quantitated by measuring the distance between alveolar walls (Lm) and the surface-to-volume ratio (S/V) of the gas-exchange structures (septa). The Lm in cottonseed oil-treated rats was 86 μm ± 5.5 μm (N=3) compared to 74.0 μm ± 1.0 μm (N=3) in RARα antagonist-treated rats (N=3; P=0.05 by Mann Whitney nonparametric analysis). The SIN was 470 μm'1 ±32 μm"1 (Ν=3) in cottonseed oil-treated rats compared to 541 μm"1 ±7 μm"1 (N=3) in RARα antagonist-treated rats (P=0.05). Lung volume was the same in both rat groups but surface area was smaller (714 cm2 ±69 cm2) in cottonseed oil-treated rats than in RARα antagonist-treated rats (820 cm2± 82 cm2, P=0.12).
These data demonstrate that treatment of immature rats with a RARα antagonist promotes septation of the saccules of the gas-exchange region, resulting in smaller and more numerous alveoli and a higher surface to volume ratio, and clearly suggest that antagonism of the RARα receptor results in the up-regulation of naturally occurring, spontaneous alveolus formation. A clear implication of this finding is that the inverse is also true: that agonist activity at the RARα receptor is inhibitory for septation and alveolar development. Thus, therapeutic treatment of mammals with a RARα antagonist will promote the growth of septa.
It is quite surprising, in light of the previous finding that ATRA (an RAR-specific agonist of RARα, RARβ, and RARγ) stimulates septation, that an antagonist of RARα is able to promote septation and alveolar development.
These data therefore provide evidence that alveolus formation is promoted in vivo by inhibition of RARα, and that stimulation of the RARα receptor is not required.
The data also indicate that the increase in lung air volume seen in the first few days is an event independent from the presence or absence of RAR receptors or the presence or absence of an RAR modulating ligand. The septation stage of lung development can therefore be uncoupled from the increase in lung volume seen immediately post birth. Thus, modulating of RAR receptors can be used to specifically affect septation without modulating other events in alveolar formation.
Thus, signal transduction through RAR receptors appears to be an endogenous modulator of alveolus formation. The generation of agents having specific RAR modulating activity (e.g., RARα antagonist activity) permits more specific targeting of alveolar formation. In addition, treatment with a RARα antagonist plus all-trans retinoic acid may well augment the effect of either agent alone, allowing the use of lower doses of these drugs.
It will be recognized that the foregoing examples and preferred embodiments are exemplary only, and that the invention is defined solely by the claims that conclude this specification.
Claims
1. A composition for the treatment or prevention of alveolar destruction in a mammal comprising a pharmaceutically effective amount of an RARα antagonist having specific RAR modulating activity and is not an RARβ agonist.
2. The composition of claim 1 wherein said RARα antagonist is not specific to RARβ
3. The composition of claim 1 wherein said RARα antagonist is not specific to RARγ.
4. The composition of claim 1 wherein said RARα antagonist is also an RARβ antagonist.
5. The composition of claim 1 wherein said composition further comprises said RARα antagonist in dissolved form.
6. An aerosol for pulmonary delivery of a pharmaceutical composition, said pharmaceutical composition comprising an RARα antagonist having specific RAR modulating activity, wherein said RARα antagonist is not an agonist of RARβ.
7. The aerosol of claim 6 wherein said RARα antagonist is not specific to RARγ.
8. The aerosol of claim 6 wherein said RARα antagonist is an RARγ agonist.
9. The aerosol of claim 6 wherein said RARα antagonist is not specific to RARβ or RARγ.
10. A method for the treatment or prevention of alveolar destruction in a mammal comprising the step of administering to said mammal a therapeutically effective amount of an RARα antagonist having specific RAR modulating activity, wherein said RARα antagonist is not an agonist of RARβ.
11. The method of claim 10 wherein said RARα antagonist is not specific to RARβ.
12. The method of claim 10 wherein said RARα antagonist is not specific to RARγ.
13. The method of claim 10 wherein said RARα antagonist is not specific to RARβ or RARγ.
14. The method of claim 10 wherein said composition is administered in the form of an inhalant.
15. A method to increase the gas-exchange surface area of a mammalian lung in a mammal in need thereof comprising the step of administering a therapeutically effective amount of an RARα antagonist having specific RAR modulating activity to said mammal.
16. The method of claim 15 wherein said RARα antagonist is not a RARβ agonist.
17. The method of claim 15 wherein said RARα antagonist is not a RARγ agonist.
18. The method of claim 15 wherein said RARα antagonist is not specific to RARβ or RARγ.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001251400A AU2001251400A1 (en) | 2000-04-07 | 2001-04-06 | Treatment of pulmonary disorders by inducing alveoli formation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19554100P | 2000-04-07 | 2000-04-07 | |
US60/195,541 | 2000-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001076591A1 true WO2001076591A1 (en) | 2001-10-18 |
Family
ID=22721800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011276 WO2001076591A1 (en) | 2000-04-07 | 2001-04-06 | Treatment of pulmonary disorders by inducing alveoli formation |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001251400A1 (en) |
WO (1) | WO2001076591A1 (en) |
-
2001
- 2001-04-06 AU AU2001251400A patent/AU2001251400A1/en not_active Abandoned
- 2001-04-06 WO PCT/US2001/011276 patent/WO2001076591A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [online] NALTNER ET AL.: "Retinoic acid stimulation of the human surfactant protein B promoter is thyroid transcription factor 1 site-dependent", XP002941166, accession no. STN Database accession no. 2000:323718 * |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 1, 7 January 2000 (2000-01-07), pages 56 - 62 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001251400A1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080125489A1 (en) | Methods and compositions for the treatment and prevention of lung disease | |
Pomposelli et al. | Role of biochemical mediators in clinical nutrition and surgical metabolism | |
Scalia et al. | C‐peptide inhibits leukocyte‐endothelium interaction in the microcirculation during acute endothelial dysfunction | |
Brenner et al. | Endothelium-dependent vascular responses. Mediators and mechanisms. | |
US5981586A (en) | Methods for treating proliferative and inflammatory skin diseases | |
KR100394157B1 (en) | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases | |
Lotan et al. | Enhanced efficacy of combinations of retinoic acid-and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation | |
Datta et al. | Endogenous and exogenous nitric oxide in the pedunculopontine tegmentum induces sleep | |
US10813905B2 (en) | Methods of treating sickle cell disease and related disorders using fumaric acid esters | |
KR20010015807A (en) | Use of 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease | |
US20070238791A1 (en) | Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators | |
JP2003532622A (en) | Nitric oxide donor induces neurogenesis | |
JP2002542284A (en) | Tetrac pharmaceutical compositions and methods of use | |
US6303648B1 (en) | Methods and compositions for the treatment and prevention of lung disease | |
MXPA06013256A (en) | Treating seizures using ice inhibitors. | |
WO2003007953A1 (en) | Methods and compositions for modulating t-type calcium channels | |
Coughlan et al. | Differential relaxant effect of high concentrations of intravenous anesthetics on endothelin-constricted proximal and distal canine coronary arteries | |
Konturek et al. | Direct inhibition of gastric secretion and mucosal blood flow by arachidonic acid. | |
WO2001076591A1 (en) | Treatment of pulmonary disorders by inducing alveoli formation | |
US6972175B2 (en) | Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods | |
Hamba et al. | Expression of c-fos-like protein in the rat brain after injection of interleukin-1-beta into the gingiva | |
HUT73793A (en) | Synergetic compositions containing ligands affecting on at least one rxr and at least one rar-alfa receptor | |
WO2003066080A1 (en) | Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans | |
WO2000061182A2 (en) | Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist | |
Braquet et al. | Effect of platelet-activating factor on platelets and vascular endothelium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |